tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
BioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating
PremiumRatingsBioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating
25d ago
BioAge Labs announces $75M common stock offering
Premium
The Fly
BioAge Labs announces $75M common stock offering
25d ago
BioAge Labs management to meet with Piper Sandler
Premium
The Fly
BioAge Labs management to meet with Piper Sandler
25d ago
Vanguard Total Stock Market ETF (VTI) Daily Update—1/15/26
PremiumMarket NewsVanguard Total Stock Market ETF (VTI) Daily Update—1/15/26
1M ago
BioAge Labs: Early-Stage NLRP3-Targeting Promise with Encouraging hsCRP Data, but Balanced Risk-Reward Supports Hold
Premium
Ratings
BioAge Labs: Early-Stage NLRP3-Targeting Promise with Encouraging hsCRP Data, but Balanced Risk-Reward Supports Hold
1M ago
BioAge Labs advances BGE-102 with strong Phase 1 data
Premium
Company Announcements
BioAge Labs advances BGE-102 with strong Phase 1 data
1M ago
BioAge Labs announces interim Phase 1 data for BGE-102
PremiumThe FlyBioAge Labs announces interim Phase 1 data for BGE-102
2M ago
BioAge Labs Advances Clinical Programs Amid Financial Progress
Premium
Company Announcements
BioAge Labs Advances Clinical Programs Amid Financial Progress
3M ago
BioAge Labs price target raised to $15 from $10 at Citi
Premium
The Fly
BioAge Labs price target raised to $15 from $10 at Citi
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100